UCPH spin-out to develop the future's obesity medicine with Novo Nordisk

Less than a year after Embark Biotech was spun out from University of Copenhagen, the new Danish biotech company has entered a comprehensive collaboration with Novo Nordisk to develop a brand new class of obesity drugs.

Embark Biotech is based in Cobis Science Park Photo: Jan Bjarke Mindegaard

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles